Vaxcyte Announces Closing of $690 Million Public Offering

SAN CARLOS, Calif., Oct. 28, 2022 (GLOBE NEWSWIRE) — Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation firm engineering high-fidelity vaccines to guard humankind from the implications of bacterial ailments, introduced at this time the closing of its beforehand introduced underwritten public providing of 17,812,500 shares of widespread inventory at a public providing value of $32.00 per share and pre-funded warrants to buy 3,750,000 shares of widespread inventory at a public providing value of $31.999 per underlying share. This consists of the train in full by the underwriters of their choice to buy as much as 2,812,500 extra shares of widespread inventory on the public providing value per share, much less underwriting reductions and commissions. The combination gross proceeds to Vaxcyte from this providing have been roughly $690.0 million, earlier than deducting underwriting reductions and commissions and different providing bills payable by Vaxcyte.

BofA Securities, Jefferies, SVB Securities, Evercore ISI and Guggenheim Securities acted as joint book-running managers for the providing. Cantor acted as lead supervisor for the providing. Needham & Company and BTIG acted as co-managers for the providing.

A shelf registration assertion regarding the provided securities was filed with the Securities and Exchange Commission (SEC), and was robotically efficient upon submitting on July 2, 2021. A ultimate prospectus complement and accompanying prospectus regarding the providing has been filed with the SEC and is offered on the SEC’s web site, positioned at www.sec.gov. Copies of the ultimate prospectus complement and the accompanying prospectus regarding this providing could also be obtained from BofA Securities NC1-004-03-43, Attention: Prospectus Department, 200 North College Street, third Floor, Charlotte, North Carolina 28255 or by e mail at [email protected]; Jefferies LLC, Attention: Equity Syndicate Department, 520 Madison Avenue, New York, New York 10022, by phone at 1-877-821-7388, or by e mail at [email protected]; SVB Securities LLC, Attention: Syndicate Department, 53 State Street, fortieth Floor, Boston, MA 02109, by e mail at [email protected] or by cellphone at (800) 808-7525, ext. 6105; Evercore Group L.L.C., Attention: Equity Capital Markets, 55 East 52nd Street, thirty fifth Floor, New York, New York 10055, by phone at 1-888-474-0200 or by e mail at [email protected]; and Guggenheim Securities, LLC, Attention: Equity Syndicate Department, 330 Madison Avenue, eighth Floor, New York, New York 10017, by phone at (212) 518-9544, or by e mail at [email protected].

This press launch shall not represent a suggestion to promote or a solicitation of a suggestion to purchase these securities nor shall there be any sale of these securities in any state or jurisdiction through which such supply, solicitation or sale can be illegal previous to registration or qualification below the securities legal guidelines of any such state or jurisdiction.

About Vaxcyte
Vaxcyte is a vaccine innovation firm engineering high-fidelity vaccines to guard humankind from the implications of bacterial ailments. The Company is growing broad-spectrum conjugate and novel protein vaccines to stop or deal with bacterial infectious ailments. Vaxcyte’s lead candidate, VAX-24, is a 24-valent, broad-spectrum pneumococcal conjugate vaccine being developed for the prevention of invasive pneumococcal illness. Vaxcyte is re-engineering the way in which extremely complicated vaccines are made by way of fashionable artificial methods, together with superior chemistry and the XpressCF™ cell-free protein synthesis platform, solely licensed from Sutro Biopharma, Inc. Unlike standard cell-based approaches, the Company’s system for producing difficult-to-make proteins and antigens is meant to speed up its skill to effectively create and ship high-fidelity vaccines with enhanced immunological advantages. Vaxcyte’s pipeline additionally consists of VAX-XP, a PCV with protection of 31 strains; VAX-A1, a prophylactic vaccine candidate designed to stop Group A Strep infections; and VAX-PG, a therapeutic vaccine candidate designed to gradual or cease the development of periodontal illness. Vaxcyte is pushed to eradicate or deal with invasive bacterial infections, which have critical and dear well being penalties when left unchecked.

Contacts:

Andrew Guggenhime, President and Chief Financial Officer
Vaxcyte, Inc.
650-837-0111
[email protected]

Janet Graesser, Vice President, Corporate Communications and Investor Relations
Vaxcyte, Inc.
917-685-8799
[email protected]